Target Amino acid transportClass Synthetic amino acidOther names FACBC
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [¹⁸F]fluciclovine Syntheses and QC ↗ | Imaging | 132.12 | 14 | Phase 3 | Axumin US EU FR JP |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [18F]fluciclovineNCT06159335 · Solid tumors (multiple indications) | Phase 3 | Recruiting | University of Wisconsin, Madison | 1 |
| [18F]fluciclovine2024-517095-38-00 · Myeloma | Phase 3 | Recruiting | Oslo University Hospital HF | 1 |
| GABLE · [18F]fluciclovineNCT06319027 · Brain (glioma, medulloblastoma…) | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 1 |
| CONCORDANT · [18F]fluciclovineNCT05554302 · Solid tumors (multiple indications) | Phase 2 | Recruiting | Baptist Health South Florida | 1 |
| [18F]fluciclovineNCT04689048 · Solid tumors (multiple indications) | Phase 1 | Recruiting | Baptist Health South Florida | 1 |
| FACILITATE · [18F]fluciclovineNCT06048094 · Solid tumors (multiple indications) | Phase 1 | Recruiting | Baptist Health South Florida | 1 |
| [18F]fluciclovineNCT05555550 · Brain (glioma, medulloblastoma…) | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 1 |
| [18F]fluciclovineNCT06062745 · Prostate – mCRPC | Phase 1 | Recruiting | Brigham and Women's Hospital | 1 |
| [18F]fluciclovineNCT06055790 · Other | Phase 1 | Recruiting | University of Arizona | 1 |
| GBM · [18F]fluciclovineNCT06613841 · Brain (glioma, medulloblastoma…) | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 1 |
| [18F]fluciclovineNCT05553041 · Brain (glioma, medulloblastoma…) | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 1 |
| [18F]fluciclovineNCT07569926 · Prostate – localised / recurrence | No phase | Recruiting | Blue Earth Diagnostics | 1 |
| [18F]fluciclovineNCT05722925 · Prostate – localised / recurrence | No phase | Active, not recruiting | OHSU Knight Cancer Institute | 1 |
| [18F]fluciclovineNCT06706921 · Prostate – mCRPC | No phase | Recruiting | VA Greater Los Angeles Healthcare System | 1 |
| 2026-06 | EMPIRE-2 · mixedIn 134 patients with recurrence after prostatectomy, randomized between the two tracers, PET changes the radiotherapy decision in 29% (fluciclovine) and 42% (PSMA) of cases, with no significant difference between tracers. Radiation fields change more often with fluciclovine. | Radiology ↗ |
486 publications in PubMed for the query below; the most recent:
fluciclovine[tiab] OR FACBC[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Fluciclovine. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fluciclovine/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.